Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

Summary

This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.

Timeline

Start

2018-01-19

Primary completion

2020-01-23

Completion

2020-01-23

Outcome

Met primary endpoint

release “DM199 met primary safety and tolerability endpoints and no DM199-related serious adverse events were noted in the study.” diamedica.com ↗

Publications

• Campbell BC, Kasner SE, Lista AD, Volpi JJ, Kleinig TJ, Cordato D, Dewey HM, Choi PM, Garcia-Esperon C, Sahathevan R, Wijeratne T, Wong AA, Ghia D, Cloud GC, Giuffre M, Bath PM; ReMEDy1 Investigators. Safety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1). Int J Stroke. 2025 Nov 6:17474930251396480. doi: 10.1177/17474930251396480. Online ahead of print.

Drugs

Indications